Many biomedically relevant proteins require something beyond standard expression in E. coli. Mammalian expression systems offer the advantages of proper folding and post-translational modifications not possible in prokaryotic cells. Recombinant antibodies are increasingly important subjects for research, and mammalian expression systems are popular platforms for these studies. Being able to rely on vectors that produce high expression of functional antibodies is a critical piece of the puzzle.
- Capturem technology
- Antibody immunoprecipitation
- His-tag purification
- Other tag purification
- Phosphoprotein and glycoprotein purification
- Matchmaker Gold yeast two-hybrid systems
- Expression systems
High expression of functional OKT3 monoclonal antibodies in mammalian cells
pHEK293 Ultra Expression Vectors
TAR-Tat transactivation for ultra-high protein expression in mammalian cells
The pHEK293 Ultra Expression Vector systems exploit the HIV-1 TAR-Tat transcriptional activation mechanism to express proteins of interest at ultra-high levels in human HEK 293 cells. These systems are capable of providing protein expression up to 10 times higher than what is typically obtained with vectors containing CMV-derived promoters. Please visit our overview page to learn more about this transcriptional activation mechanism.
The pHEK293 Ultra Expression system is available in two formats. The single-vector format (Cat. # 3390) allows for high expression of your protein of interest with the convenience of single-plasmid transfection. The double-vector system (Cat. # 3392) includes a separate Enhancer Vector. While experiments with this system will require cotransfection of cells with both plasmids, they will give you the ability to optimize expression levels by varying the ratio of the two vectors.
Quantification of highly expressed monoclonal antibodies
The double-vector system (pHEK293 Ultra Expression Vector II, Cat. # 3392) was used to produce anti-human CD3 IgG monoclonal antibody clone OKT3. The pHEK293 Ultra Expression Vector II system was compared to a negative control and a vector with a CMV-derived promoter (pBApo-CMV DNA). Protein expression was examined in adherent and suspension cells transfected as shown in the table below. Cells were cotransfected with IgG heavy chain (HC) and light chain (LC) expression constructs. Culture samples taken at 2, 5, 7, and 9 days after transfection showed high expression for all of the pHEK293 vector conditions; expression levels were 5- to 7-fold higher than with the CMV vector.
|Experimental condition||Cell type||IgG heavy chain (HC) expression vector||IgG light chain (LC) expression vector||pHEK293 Enhancer Vector amount (µg)|
|Vector||Amount (µg)||Vector||Amount (µg)|
|1||Adherent HEK 293T cells||pBApo-CMV1/HC||0.5||pBApo-CMV/LC||0.5||n/a|
|2||Vector II2/HC||0.5||Vector II/LC||0.5||0.008|
|3||Vector II/HC||0.5||Vector II/LC||0.5||0.2|
|4||Negative Control||n/a||Negative Control||n/a|
|5||Suspension HEK 293 cells||pBApo-CMV/HC||15||pBApo-CMV/LC||15||n/a|
|6||Vector II/HC||15||Vector II/LC||15||0.24|
|7||Vector II/HC||15||Vector II/LC||15||6|
|8||Negative Control||n/a||Negative Control||n/a||n/a|
- pBApo-CMV DNA vector
- pHEK293 Ultra Expression Vector
Native SDS-PAGE was performed with these two purified samples under reducing and non-reducing conditions. Results show that OKT3 expressed with the pHEK293 Ultra Expression Vector II system produced the expected band pattern (Lanes 2 in gels shown below), suggesting that this highly expressed, purified antibody has the correct structure.
Functional evaluation of the expressed antibody in mammalian cell culture
While ultra-high expression and correct structure are good indicators, characterizing antibody function is critical. As a first assessment, flow cytometry was used to look at the binding activity of purified OKT3 from the above experimental samples and a positive control sample obtained from hybridomas. With the positive control set at 100%, the pBApo-CMV DNA vector sample had 109.3% activity and the pHEK293 Ultra Expression Vector II sample had 119% activity. Thus, the binding activity of the overexpressed antibody from the pHEK293 Vector II system was comparable to the positive control.
The OKT3 monoclonal antibody binds to antigen receptors on the surface of human T lymphocytes, resulting in activation and expansion of T cells. The purified OKT3 samples were evaluated for these lymphocyte proliferation effects in vitro. Addition of the various OKT3 samples promoted clustering and activation of lymphocytes in all instances as observed by microscopy (Panel A, below). OKT3 produced by the pHEK293 Ultra Expression Vector II system resulted in expansion comparable to that of the hybridoma control, as well as that of the other vector (Panel B, below).
On Day 10, the cells were harvested to analyze the levels of the surface antigens CD3, CD4, and CD8 by flow cytometry. Lymphocyte activation by OKT3 obtained from the pHEK293 Ultra Expression Vector II system displayed surface antigen patterns comparable to those of other OKT3 sources. These results indicate that OKT3 produced by this system has the same lymphocyte stimulatory capacity and high productivity as antibodies produced by other systems.
pHEK293 Ultra Expression Vectors provide ultra-high expression of recombinant proteins, including antibodies, in mammalian cells. While the single-vector system has the advantage of convenience, the double-vector system grants the opportunity to optimize expression levels of the protein of interest. With antibody expression levels shown to be 5–7 times higher than those obtained from vectors with traditional CMV-derived promoters, it is possible to produce large quantities of antibodies using HEK 293 cells. In addition, the production of functional protein underscores this system's usefulness when proper folding and/or post-translational modifications are necessary.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.